verified SJR 0,956 · Q2 • database Scopus / SJR & Web of Science indexed

United States · Lippincott Williams and Wilk...

workspace_premium Q2 — Oncology lock Subscription

Cancer Journal

Cancer Journal is a journal indexed in SJR in Oncology and Cancer Research with an H index of 107. It has an SJR impact factor of 0,956 and it has a best quartile of Q2. It has an SJR impact factor of 0,956.

Cancer Journal focuses its scope in these topics and keywords: cancer, adolescents, pancreatic, boxnovel, oral, early, young, detectioncurrent, adults, health, ...

ISSN: 1528-9117

Publisher: Lippincott Williams and Wilkins

Category: Oncology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,956 Q2

H-index 107

Acceptance rate pie_chart

25% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,956

H-index

107

Docs (year)

Docs 3y

197

Total refs

4035

Cites 3y

471

Citable 3y

180

Cites/Doc 2y

2.1

Ref/Doc

66.15

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Book review

Written Parental Consent and the Use of Incentives in a Youth Smoking Prevention Trial: A Case Study From Project SPLASH

Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia

Correspondence Letter

Comparing the Use of Protons and Carbon Ions for Treatment

Comparing Radiotherapy to Prostatectomy for High-Risk Prostate Cancer

Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia

Closing Comments

Clinically Lymph Node Positive Prostate Cancer

Circulating Tumors Cells as Biomarkers

Chimeric Antigen Receptor T Cells in Chronic Lymphocytic Leukemia

Building a Better Body of Evidence: New Opportunities to Strengthen Evaluation Utilization

SHOW MORE ARTICLES

Bruton Tyrosine Kinase Inhibitors

4-1BB Chimeric Antigen Receptors

Biochemical Outcome for Hormone-Na??ve Patients with High-Risk Prostate Cancer Managed with Permanent Interstitial Br achy therapy and Supplemental External-Beam Radiation

BCL-2 Inhibitors, Present and Future

Attributes Contributing to Superior Outcomes in the Surgical Management of Early-Stage Lung Cancer and Examples of Implementing Improvement

Antibodies for Molecular Imaging of Cancer

An Integral Approach to Evaluating Outcome Evaluation Training

An Exploratory Study of Process Use: Findings and Implications for Future Research

Adverse Events in Cancer Genetic Testing

A Truly Useful Bat is One Found in the Hands of a Slugger

A Three-Step Approach to Teaching Logic Models

A New Realistic Evaluation Analysis Method

FAQs

Cancer Journal has an SJR of 0,956 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Cancer Journal is 25%.

Cancer Journal

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Cancer Journal?

What is the APC / publication cost?

What is the acceptance rate?